OncoDNA is fully committed to increase patient access to the right treatment
options and when needed, to the most relevant clinical trials. That is the essence of OncoDNA’s
Precision Enrollment services, and the reason inspiring us to develop the most comprehensive
approach available on the market.
Many targeted clinical trials are not related solely to gene alterations but are depending on to
the expression of a specific protein, the presence of a novel mRNA transcript or the occurrence
of a methylation event. Hence, the best treatment options cannot be established by relying
solely on DNA analysis. OncoDNA characterizes patients by NGS and searches for specific SNVs,
CNVs, Indels and translocations but is also relying on molecular pathology tools for monitoring
the expression of specific receptors or biomarkers using IHC, by assessing methylation status,
…. Thanks to this comprehensive characterization of the patient solid and liquid biopsy, OncoDNA
provides the only truly comprehensive picture of patient’s cancer. This approach offers the
highest chances to find a match between a patient looking for an effective treatment and a
biopharma company recruiting patients for their trial.
OncoDNA collects additional clinical information about the patient disease prior to testing and
monitors disease evolution after the treatment is started. This meets the increasing demand from
pharma partners who want to have access to a patient with extensive medical and clinical
history. OncoSHARE reports contain a timeline of the disease where all the significant clinical
events are listed, from the diagnostic data and treatment regimens followed by the patient
before OncoDNA testing to treatment efficacy monitoring and clinical data related to OncoTRACE
This approach provides the patient, the treating physician and the biopharma sponsor with a
unique longitudinal view about the clinical landscape of the disease.
Clinical trials in oncology are challenging for biopharma companies. In 2015, approximately 630
breast cancer trials, 470 lung cancer trials and 340 colorectal
cancer trials were initiated. In 2016, the number of new trials registered every
month peaked at 500(*)! This means that a lot of cancer patients need to be
recruited for these trials. Furthermore, many clinical trials are evaluating targeted
or immuno therapies which require very specific patient profiles harbouring
a precise molecular alteration or expressing a unique biomarker. An increasing number of
biopharmas are involved in cancer treatment development, which means, for the patients’ benefit,
additional compounds being tested in clinical trials and a growing demand for enrolling patients
in these clinical trials. Also, as many new drugs are targeting specific molecular events,
eligible patients are more specific and difficult to find.
Our job ? To help patients and biopharmas with targeted recruitment. Our program is driven by the
fast growing number of patients and oncologists using OncoDNA solutions.
(*) : Mining ClinicalTrials.gov – Institutions, Funding, and Areas of Focus
| Michael Shea |
January 18, 2017